Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H26N2O5S |
| Molecular Weight | 394.485 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC1=CC=CC=C1OCCN[C@H](C)CC2=CC=C(O)C(=C2)S(N)(=O)=O
InChI
InChIKey=UIDNSBDGPKUJHU-CQSZACIVSA-N
InChI=1S/C19H26N2O5S/c1-3-25-17-6-4-5-7-18(17)26-11-10-21-14(2)12-15-8-9-16(22)19(13-15)27(20,23)24/h4-9,13-14,21-22H,3,10-12H2,1-2H3,(H2,20,23,24)/t14-/m1/s1
| Molecular Formula | C19H26N2O5S |
| Molecular Weight | 394.485 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:35:48 GMT 2023
by
admin
on
Sat Dec 16 11:35:48 GMT 2023
|
| Record UNII |
L3ZWN2HON0
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
176223-33-9
Created by
admin on Sat Dec 16 11:35:49 GMT 2023 , Edited by admin on Sat Dec 16 11:35:49 GMT 2023
|
PRIMARY | |||
|
L3ZWN2HON0
Created by
admin on Sat Dec 16 11:35:49 GMT 2023 , Edited by admin on Sat Dec 16 11:35:49 GMT 2023
|
PRIMARY | |||
|
9800777
Created by
admin on Sat Dec 16 11:35:49 GMT 2023 , Edited by admin on Sat Dec 16 11:35:49 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE |
PLASMA
|
||
|
PARENT -> METABOLITE |
URINE
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
RBx9001; Indication: Urology; Development Stage: Pre-clinical stage
|
||
|
ACTIVE MOIETY |
Originator: Ranbaxy Laboratories; Mechanism of Action: Undefined mechanism; Highest Development Phase: Discontinued for Benign prostatic hyperplasia; Most Recent Events: 20 Oct 2008 Ranbaxy Laboratories has been acquired by Daiichi Sankyo Company, 02 May 2004 Phase-I clinical trials in Benign prostatic hyperplasia in India (unspecified route), 02 May 2004 Ranbaxy has received approval from the Drugs Controller General of India to begin phase I trials with RBx 9001
|
